Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DNGPW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RN765C
|
|||||
| Synonyms |
RN 765C; RN-765C
Click to Show/Hide
|
|||||
| Organization |
Rinat Neuroscience Corp.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
EGFR Ab-L
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Auristatin 0101
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
AcLys-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
RN765C is generated by conjugating AcLys-VC-PABC-PF-06380101 to the transglutaminase tag (GGLLQGPP) located at the C-terminus of the antibody light chain, providing a maximum DAR of 2.
|
|||||
| Combination Type |
AcLys-VC-PABC-PF-06380101
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.